Barrington raised the firm’s price target on Bioventus (BVS) to $14 from $13 and keeps an Outperform rating on the shares. The firm cites the company’s “strong” Q4 report and better than expected fiscal 2026 outlook for the target boost.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BVS: